Cargando…

Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells

Use of the antibody trastuzumab to kill HER2+ breast cancer cells is an attractive therapy because of its specificity and minimal adverse effects. However, a large fraction of HER2+ positive patients are or will become resistant to this treatment. No other markers are used to determine sensitivity t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kute, Timothy, Stehle, Jr., John R., Ornelles, David, Walker, Natalie, Delbono, Osvaldo, Vaughn, James P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2012
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489736/ https://www.ncbi.nlm.nih.gov/pubmed/23162748 http://dx.doi.org/10.4161/onci.20447

Ejemplares similares

The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC
por: Guti, Eliza, et al.
Publicado: (2022)

Development of a Macrophage-Based ADCC Assay
por: Uccellini, Melissa B., et al.
Publicado: (2021)

Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar
por: Kim, Seokkyun, et al.
Publicado: (2017)

ADCC potency assay: increased standardization with modified lymphocytes
por: Bretaudeau, Laurent, et al.
Publicado: (2011)

Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era
por: Mandó, Pablo, et al.
Publicado: (2021)

Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition
por: Di Modica, Martina, et al.
Publicado: (2015)

Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis
por: Macagno, Marco, et al.
Publicado: (2022)

Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines
por: Boero, Silvia, et al.
Publicado: (2015)

Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines
por: Boero, Silvia, et al.
Publicado: (2016)

ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response
por: Ehlers, Femke A. I., et al.
Publicado: (2021)

The Yin and Yang of ADCC-Mediating Antibodies
por: Robert-Guroff, Marjorie
Publicado: (2016)

Taking advantage of a high-throughput flow cytometer for the implementation of an ADCC assay for regulatory compliance
por: Camacho-Sandoval, Rosa, et al.
Publicado: (2020)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer
por: Li, Feifei, et al.
Publicado: (2022)

Anti-HER2 mAb plus calicheamicin immunoconjugate linked on liposomal vinorelbine induces ADCC and apoptosis in HER2-positive high grade DCIS
por: Giannos, J, et al.
Publicado: (2000)

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
por: Cheng, Huan, et al.
Publicado: (2014)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results
por: Ocaña, Alberto, et al.
Publicado: (2018)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
por: DiPeri, Timothy P., et al.
Publicado: (2023)

γδT cells are ADCC effectors in elite HIV controllers
por: Poonia, Bhawna, et al.
Publicado: (2010)

ADCC: An underappreciated correlate of cross-protection against influenza?
por: de Vries, Rory D., et al.
Publicado: (2023)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
por: Lammers, Philip E., et al.
Publicado: (2018)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient
por: Lu, Nu T., et al.
Publicado: (2015)

Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy
por: Pereira, Patrícia M. R., et al.
Publicado: (2018)

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance
por: Upton, Rosalynd, et al.
Publicado: (2021)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
por: Maadi, Hamid, et al.
Publicado: (2018)

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
por: Li, Xin, et al.
Publicado: (2018)

Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines
por: Burguin, Anna, et al.
Publicado: (2020)

Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases
por: Mills, Matthew N., et al.
Publicado: (2021)

A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies
por: Lallemand, Christophe, et al.
Publicado: (2017)

Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
por: Fiszman, Gabriel L., et al.
Publicado: (2011)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
por: Oostra, Drew R, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_f94mbnmvdgc4dac0a6l7gqteki